全文获取类型
收费全文 | 41893篇 |
免费 | 3474篇 |
国内免费 | 700篇 |
专业分类
耳鼻咽喉 | 240篇 |
儿科学 | 368篇 |
妇产科学 | 666篇 |
基础医学 | 2711篇 |
口腔科学 | 271篇 |
临床医学 | 5312篇 |
内科学 | 4145篇 |
皮肤病学 | 324篇 |
神经病学 | 794篇 |
特种医学 | 755篇 |
外科学 | 2810篇 |
综合类 | 6274篇 |
现状与发展 | 1篇 |
一般理论 | 4篇 |
预防医学 | 10210篇 |
眼科学 | 115篇 |
药学 | 3041篇 |
51篇 | |
中国医学 | 801篇 |
肿瘤学 | 7174篇 |
出版年
2024年 | 42篇 |
2023年 | 703篇 |
2022年 | 1225篇 |
2021年 | 1881篇 |
2020年 | 1868篇 |
2019年 | 1997篇 |
2018年 | 1970篇 |
2017年 | 1766篇 |
2016年 | 1434篇 |
2015年 | 1517篇 |
2014年 | 3681篇 |
2013年 | 3373篇 |
2012年 | 3006篇 |
2011年 | 2985篇 |
2010年 | 2281篇 |
2009年 | 2104篇 |
2008年 | 2375篇 |
2007年 | 1960篇 |
2006年 | 1616篇 |
2005年 | 1253篇 |
2004年 | 1116篇 |
2003年 | 951篇 |
2002年 | 560篇 |
2001年 | 584篇 |
2000年 | 459篇 |
1999年 | 367篇 |
1998年 | 312篇 |
1997年 | 284篇 |
1996年 | 284篇 |
1995年 | 220篇 |
1994年 | 207篇 |
1993年 | 155篇 |
1992年 | 114篇 |
1991年 | 120篇 |
1990年 | 89篇 |
1989年 | 82篇 |
1988年 | 60篇 |
1987年 | 63篇 |
1986年 | 45篇 |
1985年 | 120篇 |
1984年 | 142篇 |
1983年 | 104篇 |
1982年 | 134篇 |
1981年 | 93篇 |
1980年 | 90篇 |
1979年 | 80篇 |
1978年 | 48篇 |
1977年 | 30篇 |
1976年 | 39篇 |
1975年 | 28篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
21.
《Radiologia》2022,64(3):256-265
Breast cancer is the second most common cancer in Peruvian women. Due to limitations in national breast cancer screening programs, especially in rural areas, more than 50% of cases of breast cancer in Peru are diagnosed in advanced stages. In collaboration with a local clinic registered as a nongovernmental organization (CerviCusco), RAD-AID International aims to create a sustainable diagnostic structure to improve breast cancer screening in Cuzco. With the support of local, national, and international partners that have collaborated in analyzing radiological resources, raising awareness in the population, acquiring equipment, training clinical staff, and building referral networks, our teams of radiologists, included in the RAD-AID team, have participated in training CerviCusco staff in breast ultrasound, thus enabling additional training for radiology residents through a regulated international collaboration. 相似文献
22.
目的:分析手术治疗结节性甲状腺肿合并甲状腺癌的临床效果。方法:从2017年3月~2019年3月期间到我院接受治疗的结节性甲状腺肿合并甲状腺癌患者中选出60例完成此次研究,60例患者全部接受手术治疗,经1年的随访后对比两组患者接受治疗前后的生活质量变化情况及治疗效果。结果:接受治疗后患者的心理、身体、物质生活、社会关系等多项生活质量指标均优于治疗前,治疗前后的数据对比存在明显差异(P<0.05)。所有患者接受治疗后均为表现出较为明显的不良反应,其治疗存在较高安全性,总治疗有效率为87.50%(55/60)。结论:帮助结节性甲状腺肿合并甲状腺癌患者选择合理的手术方式,能够提高临床治疗效果,减少并发症。 相似文献
23.
24.
Cis-diamminedichloridoplatinum(II)(CDDP)-based combination chemotherapy is frequently used in gastrointestinal cancer. The synergistic mechanism of all-trans retinoic acid (ATRA), cisplatin (CDDP) and 5-fluorouracil (5-FU) in combination remains unclear. Despite their potent antitumor properties, resistance to CDDP and 5-FU develops frequently in tumors. To clarify this mechanism, we determined the sensitivity to each drug and their combination in two gastrointestinal cancer stem cells (CSCs) subpopulation.Here, we report the identification and separation of CD44+ cells from human gastric carcinoma (AGS) and human esophageal squamous cell carcinoma (KYSE-30) cancer cell lines by magnetic activated cell sorting (MACS). We allowed the CD44± cells to grow 6 days at a subtoxic concentration of ATRA and then treated with different concentration of CDDP and 5-FU for 24 h. The cytotoxicity was examined by cell proliferation MTT assay. Additionally, AO/EB staining was used for detection of apoptotic cells. In order to determine whether the growth inhibition was also associated with changes in cell cycle distribution, cell cycle analysis was performed using flow cytometry.Low concentration of ATRA (1 μM, 6days) followed by 5-FU and CDDP was found to be more effective than either drugs alone, thus resulting in synergistic cytotoxicity in Kyse-30 and AGSCD44± cells. Furthermore, there was an indication that the combination of ATRA with 5FU and CDDP caused an increase in cell cycle arrest in G2/M and G0/G1.We conclude that low concentration of ATRA enhances the cytotoxicity of CDDP and 5FU by facilitating apoptosis and cell cycle arrest in gastrointestinal CSCs and provide a rational basis for the design of novel, well-tolerated CDDP- and 5FU-based chemotherapy in human gastrointestinal carcinoma. 相似文献
25.
《药学学报(英文版)》2020,10(3):414-433
The T cell co-stimulatory molecule OX40 and its cognate ligand OX40L have attracted broad research interest as a therapeutic target in T cell-mediated diseases. Accumulating preclinical evidence highlights the therapeutic efficacy of both agonist and blockade of the OX40–OX40L interaction. Despite this progress, many questions about the immuno-modulator roles of OX40 on T cell function remain unanswered. In this review we summarize the impact of the OX40–OX40L interaction on T cell subsets, including Th1, Th2, Th9, Th17, Th22, Treg, Tfh, and CD8+ T cells, to gain a comprehensive understanding of anti-OX40 mAb-based therapies. The potential therapeutic application of the OX40–OX40L interaction in autoimmunity diseases and cancer immunotherapy are further discussed; OX40–OX40L blockade may ameliorate autoantigen-specific T cell responses and reduce immune activity in autoimmunity diseases. We also explore the rationale of targeting OX40–OX40L interactions in cancer immunotherapy. Ligation of OX40 with targeted agonist anti-OX40 mAbs conveys activating signals to T cells. When combined with other therapeutic treatments, such as anti-PD-1 or anti-CTLA-4 blockade, cytokines, chemotherapy, or radiotherapy, the anti-tumor activity of agonist anti-OX40 treatment will be further enhanced. These data collectively suggest great potential for OX40-mediated therapies. 相似文献
26.
27.
28.
29.
30.